Top Markets
Coin of the day
Vaxart, Inc. Vaxart, Inc.

Vaxart, Inc.

VXRT
Rankning i aktier #20725
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Aktiekurs
$0.5194
Marknadsvärde
$125.72M
Förändring (1 dag)
-0.12%
Förändring (1 år)
48.40%
Land
US
Handel Vaxart, Inc. (VXRT)

Kategori

Utdelningsavkastning för Vaxart, Inc. (VXRT)
Utdelningsavkastningen (TTM) för Vaxart, Inc. (aktiesymbol: VXRT) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Vaxart, Inc. (VXRT) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter
Företag Utdelningsavkastning Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH